Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
June 1, 2023
Nice, targeted option to consider in an otherwise limited therapeutic menu. It should be considered in patients with grade 2 glioma who have disease progression after surgery and could be pursued off-label in higher-grade cases with a positive IDH mutation. SEs were like other IDH inhibitors.
